Back to search results

PF-07832837 for Healthy Adults and Atopic Dermatitis

This study is testing a new drug called PF-07832837. It's a first-in-human (FIH) study, meaning it's one of the first times this drug is being given to people. The main goals are to see how safe PF-07832837 is, how well people tolerate it, and how the body processes it. The study includes healthy adults and adults with moderate to severe atopic dermatitis (a skin condition causing itchy, inflamed skin). Researchers will give different doses of PF-07832837 or a placebo (an inactive substance) to participants. The study will look for side effects and serious side effects, changes in lab tests, and heart activity (ECG) to determine if the drug is safe. The study is currently unclear on its recruitment status and aims to enroll 119 participants.

Study design
This is a randomized, placebo-controlled study with two parts. Part 1 involves healthy adults, and Part 2 involves adults with moderate to severe atopic dermatitis, with approximately 28 participants in Part 2.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for safety, lab abnormalities, and ECG changes from baseline up to Day 35 after receiving single doses.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06564389

FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients

Recruiting
PHASE1Ages 18–70InterventionalTreatment
Pfizer
~119 participants
Updated 2026-07-22 on ClinicalTrials.gov
What's tested:PF-07832837Placebo

At a glance

Recruiting sites
5 of 5 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of Participants With Treatment Emergent Treatment-Related Adverse Events (AEs) and serious adverse events (SAEs) Following single ascending doses (SAD)
Measured over Baseline up to Day 35
+10 more outcomes measured

Conditions

Healthy Participants
Atopic Dermatitis

Explore related trials

Atopic DermatitisHealthy

Where it's being run

5 sites across 4 states
California2
Florida1
Michigan1
Pennsylvania1

Study leadership

  • Pfizer CT.gov Call Center · STUDY_DIRECTOR · Pfizer

Who to contact

Pfizer CT.gov Call Center
[email protected]
1-800-718-1021
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Part 1 only: Adult participants between 18 to 55 years of age, inclusive, at the time of signing the ICD
Part 2 only: Adult participants, who at the time of screening, are between the ages of 18 and 70 years, inclusive.
Part 1 only: Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, vital sign assessments, temperature, 12-lead ECGs, laboratory tests
BMI of 17.5 to 40 kg/m2; and a total body weight \>50 kg (110 lbs)
Part 2 only: Must meet the following AD criteria:

Exclusion

Have a history of systemic infection requiring hospitalization and parenteral antimicrobial therapy, any lymphoproliferative disorder, malignancies.
Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, immunological/rheumatological disorder.
Have undergone significant trauma or major surgery within 1 month of the first dose of study intervention.
Evidence of active, latent, or inadequately treated infection with Mycobacterium tuberculosis (TB) as defined by both of the following:
Currently have active forms of other inflammatory skin diseases
Have history of or current evidence of skin conditions at the time of Day 1 that would interfere with evaluation of atopic dermatitis or response to treatment. Have active chronic or acute skin infection requiring treatment with systemic antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals within 2 weeks prior to Day 1, or superficial skin infections within 1 week prior to Day 1.
Score of ≥ 5 on the Fitzpatrick Skin Type Assessment.
History of anaphylaxis with the following exceptions: participants with sensitivity and/or anaphylaxis only to a single, avoidable allergen (eg, aspirin, penicillin, sulfa drugs, nonsteroidal anti-inflammatory drugs \[NSAIDs\], peanuts) may be enrolled, if in the opinion of the investigator, the participant is aware of the hypersensitivity and avoids the problematic allergen. Participants must carry appropriate treatment for anaphylaxis and must know how to manage anaphylactic reactions.
Any investigational or experimental therapy taken or procedure performed for AD, psoriasis, psoriatic arthritis, rheumatoid arthritis or other inflammatory diseases in the previous 1 year should be discussed with the Pfizer Medical Monitor (or designee).

What this trial measures

  • Number of Participants With Treatment Emergent Treatment-Related Adverse Events (AEs) and serious adverse events (SAEs) Following single ascending doses (SAD)Baseline up to Day 35

    An adverse event (AE) was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. An SAE was defined as any untoward medical occurrence that, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent or significant disability/incapacity; was a congenital anomaly/birth defect or other important medical events. An AE was considered as treatment emergent if the event started during the effective duration of treatment. All events that started on or after the first dosing day up to the last dose plus the lag time were considered as TEAEs.

  • Number of Participants with Clinically significant Laboratory Abnormalities Following SADBaseline up to Day 35

    Number of participants with any laboratory test abnormalities meeting pre-defined criteria was reported in this outcome measure.

  • Number of Participants with Change from Baseline in Electrocardiogram (ECG) Findings Following SADBaseline up to Day 35

    Twelve lead ECGs were obtained using an ECG machine that automatically calculated the heart rate and measured PR interval, QT interval, corrected QT (QTc) intervals and QRS complex. Clinically significant findings were determined by the investigator.

  • Number of Participants with Clinically Significant Change from Baseline in Vital Signs Following SADBaseline up to Day 35

    Vital signs included blood pressure, pulse rate, respiratory rate, oxygen saturation and oral temperature. Clinically significant findings were determined by the investigator.

  • Number of Participants with Clinically Significant Change from Baseline in Cardiac Telemetry Findings Following SADDay 1

    Cardiac telemetry was collected in Part 1 SAD cohorts only. Number of participants with any cardiac telemetry abnormalities were reported in this outcome measure.

  • Number of Participants With Treatment Emergent Treatment-Related AEs and SAEs Following multiple ascending doses (MAD)Baseline up to Day 50

    An adverse event (AE) was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. An SAE was defined as any untoward medical occurrence that, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent or significant disability/incapacity; was a congenital anomaly/birth defect or other important medical events. An AE was considered as treatment emergent if the event started during the effective duration of treatment. All events that started on or after the first dosing day up to the last dose plus the lag time were considered as TEAEs.

  • Number of Participants with Clinically significant Laboratory Abnormalities Following MADBaseline up to Day 50

    Number of participants with any laboratory test abnormalities meeting pre-defined criteria was reported in this outcome measure.

  • Number of Participants with Change from Baseline in Electrocardiogram (ECG) Findings Following MADBaseline up to Day 50

    Twelve lead ECGs were obtained using an ECG machine that automatically calculated the heart rate and measured PR interval, QT interval, corrected QT (QTc) intervals and QRS complex. Clinically significant findings were determined by the investigator.

  • Number of Participants With Treatment Emergent Treatment-Related AEs and SAEs in participants with atopic dermatitis (AD)Baseline up to Day 80

    An adverse event (AE) was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. An SAE was defined as any untoward medical occurrence that, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent or significant disability/incapacity; was a congenital anomaly/birth defect or other important medical events. An AE was considered as treatment emergent if the event started during the effective duration of treatment. All events that started on or after the first dosing day up to the last dose plus the lag time were considered as TEAEs.

  • Number of Participants with Clinically significant Laboratory Abnormalities in participants with ADBaseline up to Day 80

    Number of participants with any laboratory test abnormalities meeting pre-defined criteria was reported in this outcome measure.

  • Number of Participants with Clinically Significant Change from Baseline in Vital Signs in participants with ADBaseline up to Day 78

    Vital signs included blood pressure, pulse rate, respiratory rate, oxygen saturation and oral temperature. Clinically significant findings were determined by the investigator.